Weaver; Annie Yang

Patent Applications and Registrations

Patent applications and USPTO patent grants for Weaver; Annie Yang.The latest application filed is for "anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof".

Company Profile

8.6.13

Weaver; Annie Yang - San Mateo CA
WEAVER; Annie Yang - Cambridge MA
WEAVER; Annie Yang - South San Francisco CA
- San Mateo CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-cd71 Antibodies, Activatable Anti-cd71 Antibodies, And Methods Of Use Thereof App 20220306759 - Sagert; Jason Gary ; et al.	2022-09-29
Cancer Treatment Using Cd38 Inhibitor And/or Lenalidomide And T-cells Expressing A Chimeric Antigen Receptor App 20220202859 - TERRETT; Jonathan Alexander ; et al.	2022-06-30
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof Grant 11,267,896 - Sagert , et al. March 8, 2	2022-03-08
Activatable Anti-cd166 Antibodies And Methods Of Use Thereof App 20220023439 - CARMAN; Lori ; et al.	2022-01-27
Activatable Anti-cd166 Antibodies And Methods Of Use Thereof App 20210100913 - CARMAN; Lori ; et al.	2021-04-08
Anti-cd166 Antibodies, Activatable Anti-cd166 Antibodies, And Methods Of Use Thereof App 20200291113 - WEST; James William ; et al.	2020-09-17
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof Grant 10,745,481 - West , et al. A	2020-08-18
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof Grant 10577420 -	2020-03-03
Antibodies that bind activatable antibodies and methods of use thereof Grant 10,568,977 - Desnoyers , et al. Feb	2020-02-25
Anti-itga3 Antibodies, Activatable Anti-itga3 Antibodies, And Methods Of Use Thereof App 20190309072 - SAGERT; Jason Gary ; et al.	2019-10-10
Anti-cd71 Antibodies, Activatable Anti-cd71 Antibodies, And Methods Of Use Thereof App 20190202927 - Sagert; Jason Gary ; et al.	2019-07-04
Activatable Anti-cd166 Antibodies And Methods Of Use Thereof App 20190117789 - CARMAN; LORI ; et al.	2019-04-25
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof Grant 10,233,244 - Sagert , et al.	2019-03-19
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof Grant 10,179,817 - Sagert , et al. Ja	2019-01-15
Antibodies That Bind Activatable Antibodies And Methods Of Use Thereof App 20170326260 - Desnoyers; Luc Roland ; et al.	2017-11-16
Antibodies that bind activatable antibodies and methods of use thereof Grant 9,737,623 - Desnoyers , et al. August 22, 2	2017-08-22
Anti-cd166 Antibodies, Activatable Anti-cd166 Antibodies, And Methods Of Use Thereof App 20160355587 - West; James William ; et al.	2016-12-08
Anti-cd71 Antibodies, Activatable Anti-cd71 Antibodies, And Methods Of Use Thereof App 20160355599 - Sagert; Jason Gary ; et al.	2016-12-08
Anti-itga3 Antibodies, Activatable Anti-itga3 Antibodies, And Methods Of Use Thereof App 20160355592 - Sagert; Jason Gary ; et al.	2016-12-08
Antibodies that Bind Activatable Antibodies and Methods of Use Thereof App 20150157748 - Desnoyers; Luc Roland ; et al.	2015-06-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.